Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 63

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 63
---
 described in Part I, Item 1A of our most recent Annual Report on Form 10-K and in Part II, Item 1A of
any subsequent Quarterly Reports on Form 10-Q, in each case under the heading “Risk Factors”. Accordingly, you should not place undue reliance on these forward-looking statements. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.

2

PROSPECTUS SUMMARY This summary highlights selected information about us, this offering and information contained in greater detail elsewhere in this prospectus and in the documents incorporated by reference. This summary is not complete and does not contain all of the information that you should consider before investing in our Ordinary Shares. You should carefully read and consider this entire prospectus and the documents, including financial statements and related notes, and information incorporated by reference into this prospectus, including the financial statements and “Risk Factors” starting on page 13 of this prospectus, before making an investment decision. If you invest in our securities, you are assuming a high degree of risk. Overview Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on advancing rademikibart, a potentially best-in-classnext generation anti-interleukin-4-receptoralpha (“IL-4R a”) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (“COPD”). Corporate Information We are a Cayman Islands exempted company incorporated with limited liability and were incorporated in November 2015. Our legal name is Connect Biopharma Holdings Limited and our commercial name is Connect Biopharma. Prior to this, our business was conducted by Suzhou Connect Biopharma Co., Ltd., or Connect SZ, which was incorporated in May 2012 in Suzhou in the PRC. Our registered office in the Cayman Islands is at the offices of Appleby Global Services (Cayman) Limited at PO Box 500, 71 Fort Street, Grand Cayman, KY1-1106, Cayman Islands. Our principal executive offices and agent for service of process in the United States are located at 3580 Carmel Mountain Road, Suite 200, San Diego, California 92130. Our PRC research, development and administration facility is located at Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu